Search

everythinglearnresearchcommunity

for

Search:↓

Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.

Different types of persistent hair loss after chemotherapy respond differently to treatments.

The new patient-controlled expansion technique for breast reconstruction is safe, efficient, and cost-effective.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.

Using certain hair products may increase breast cancer risk in black women.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Low-dose oral minoxidil combined with topical minoxidil improves hair growth in breast cancer patients with therapy-induced hair loss.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

Spironolactone use is not linked to an increased risk of breast cancer, but caution is advised for high-risk patients.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Examining more lymph nodes can improve survival rates in breast cancer patients without lymph node involvement.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.

Adding chemotherapy to tamoxifen improves survival for older breast cancer patients with positive nodes.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.

The hair keratin gene KRT81 is found in both normal and breast cancer cells and helps them invade surrounding tissues.

Honey and bee pollen can help reduce menopausal symptoms in breast cancer patients.

Dihydrotestosterone causes p27 protein breakdown in ovarian and breast cancer cells by binding with SKP2.

Chemotherapy can cause significant hair thinning and changes in hair texture, while tamoxifen has a smaller effect.

Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

Hair and scalp pain is more common and severe in breast cancer patients on chemotherapy than those on tamoxifen.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

A young woman with severe symptoms of CPAN improved with intensive treatment but needed a leg amputation.

PRP treatment may help improve hair density and thickness in breast cancer patients with therapy-induced hair loss.

Scalp cooling therapy helps preserve hair during chemotherapy for most patients.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

A specific hair protein variant increases the spread of breast cancer and is linked to worse survival rates.